The therapeutic landscape for hormone receptor-positive (HR+) advanced breast cancer (BC) is moving from generalized ...

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

A common anti-nausea drug used during chemotherapy may do more than ease discomfort, it could help women with aggressive ...

Researchers find that disrupted circadian rhythms may impair gut regeneration and microbiome balance, heightening colon cancer susceptibility.

Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

"Bachelorette" alum Katie Thurston, who revealed her breast cancer diagnosis in February, received "amazing news" following three months of treatment.

Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...